ECRIN joins the CABA-HFPEF project
ECRIN is looking forward to joining an ongoing study on "CAtheter-Based Ablation of atrial fibrillation compared to conventional treatment in patients with Heart Failure with Preserved Ejection Fraction". The objective of the study is to assess whether catheter ablation for atrial fibrillation can prevent adverse cardiovascular outcomes in patients with heart failure with preserved or mildly reduced ejection fraction. The study is already running in the sponsor country of Germany as well as Austria and the Netherlands but ECRIN will be supporting its expansion to six five sites in Poland and three sites in Belgium. ECRIN will be responsible for regulatory affairs and ethics as well as local pharmacovigilance. This includes a wide variety of tasks such as the translation of some key documentation including patient information and consent forms to the national language(s) as well as continuous follow-up in these areas.
Today, it is known that heart failure triggers atrial fibrillation. The often rapid and irregular heartbeat that then occurs, in turn worsens the heart failure - a vicious circle begins. To counteract this dangerous combination of heart failure and atrial fibrillation, DZHK scientists are investigating in the CABA-HFPEF-DZHK27 study whether treatment of atrial fibrillation by so-called catheter ablation helps heart failure patients and has a positive effect on their state of health and prognosis. The study focuses on heart failure patients with preserved or only mildly reduced ejection fraction (Heart Failure with Preserved Ejection Fraction, HFPEF, and Heart Failure with mildly reduced Ejection Fraction, HFmrEF).
CABA-HFPEF-DZHK27 is now the first large, multicenter study to investigate this relationship. Across Europe, 60 centers are participating, and 1,550 patients with predefined inclusion and exclusion criteria are expected to participate through the centers. The study is designed to last five years.